RT Journal Article
SR Electronic
T1 Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 607
OP 618
DO 10.1136/ijgc-2022-003719
VO 33
IS 4
A1 Marques, Cristiana
A1 Ferreira da Silva, Filipa
A1 Sousa, Isabel
A1 Nave, Mónica
YR 2023
UL http://ijgc.bmj.com/content/33/4/607.abstract
AB Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy. Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs. The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity. Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration. This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease.